Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Zymeworks reported Q2 2026 revenue of $4.6 million, down from $48.7 million in the prior year, resulting in a net loss of $45.0 million compared to a net income of $2.3 million in 2025. The company is focusing on major second-half catalysts, including the August 25 PDUFA target action date for zanidatamab with a potential $250 million U.S. approval milestone and the anticipated closing of the Theravance Biopharma acquisition in 2H 2026.
Key figures
- Revenue
- 4590000
- Net loss
- 45000000
- Ga expenses
- 19300000
- Rd expenses
- 27400000
- Cash resources
- 322500000
- Share repurchase spend
- 49400000
- Potential zanidatamab milestone
- 250000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.